Armata Pharmaceuticals Announces $3.7M DoW Funding for Phase 3 AP‑SA02

What Happened
Armata Pharmaceuticals, Inc. announced on September 23, 2026 (via Form 8‑K) that it received $3.7 million in additional non‑dilutive funding from the U.S. Department of War (DoW). The funding is intended to support activities associated with the Phase 3 development program for AP‑SA02, the company’s intravenously administered multi‑phage product candidate for adjunct treatment of complicated Staphylococcus aureus bacteremia (including MSSA and MRSA). The company attached a press release describing the announcement to the 8‑K.

Key Details

• Amount: $3.7 million in additional funding.
• Type: Non‑dilutive funding (does not require issuing equity).
• Purpose: Support activities related to the Phase 3 development program for AP‑SA02 (IV multi‑phage therapy).
• Date filed: Form 8‑K and press release dated September 23, 2026.

Why It Matters
This funding reduces near‑term financing pressure because it is non‑dilutive and specifically earmarked for advancing AP‑SA02’s Phase 3 program, a key clinical milestone for Armata. Progress in Phase 3 can be material to the company’s pipeline value and future regulatory prospects; the DoW support also signals continued government interest in the program. Investors should note this is an additional grant to support development activities—not revenue or approval—and should monitor upcoming clinical updates and related corporate disclosures.